Exploring the role of immune checkpoint inhibitors in solitary fibrous tumors.
作者信息
Assi Tarek, Moussa Tania, Le Cesne Axel
机构信息
Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France.
Radiology Department, Gustave Roussy Cancer Campus, Villejuif, France.
出版信息
Immunotherapy. 2025 Apr;17(5):305-307. doi: 10.1080/1750743X.2025.2485670. Epub 2025 Mar 31.
Abstract
摘要
相似文献
1
Exploring the role of immune checkpoint inhibitors in solitary fibrous tumors.探索免疫检查点抑制剂在孤立性纤维性肿瘤中的作用。
Immunotherapy. 2025 Apr;17(5):305-307. doi: 10.1080/1750743X.2025.2485670. Epub 2025 Mar 31.
2
Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance.中枢神经系统孤立性纤维肿瘤：根据世界卫生组织 2021 年重新分类的病例系列。患者监测框架。
Acta Neurochir (Wien). 2024 Oct 17;166(1):414. doi: 10.1007/s00701-024-06304-7.
3
RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors.RNA 表达谱分析显示，PRAME 在孤立性纤维瘤中频繁表达，这是一个潜在的免疫治疗靶点。
Mod Pathol. 2021 May;34(5):951-960. doi: 10.1038/s41379-020-00687-5. Epub 2020 Oct 2.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.聚腺苷二磷酸核糖聚合酶抑制剂在原发性中枢神经系统恶性肿瘤患者中的作用。
Curr Treat Options Oncol. 2022 Nov;23(11):1566-1589. doi: 10.1007/s11864-022-01024-5. Epub 2022 Oct 15.
6
The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials.免疫检查点抑制剂在罕见肿瘤中的疗效：已发表临床试验的系统评价。
Crit Rev Oncol Hematol. 2022 Jun;174:103700. doi: 10.1016/j.critrevonc.2022.103700. Epub 2022 May 6.
7
Solitary fibrous tumor of the chest wall.胸壁孤立性纤维瘤
Indian J Thorac Cardiovasc Surg. 2025 Mar;41(3):367-370. doi: 10.1007/s12055-024-01848-w. Epub 2024 Oct 28.
8
Hybrid video-assisted thoracoscopic resection of a massive mediastinal solitary fibrous tumor: overcoming challenges: a case report.杂交电视辅助胸腔镜手术切除巨大纵隔孤立性纤维瘤：克服挑战：病例报告
J Med Case Rep. 2025 Jul 3;19(1):310. doi: 10.1186/s13256-025-05377-x.
9
Nanomaterials and immune checkpoint inhibitors in cancer immunotherapy: the synergistic innovation prospects.癌症免疫治疗中的纳米材料与免疫检查点抑制剂：协同创新前景
Front Immunol. 2025 Jun 4;16:1582774. doi: 10.3389/fimmu.2025.1582774. eCollection 2025.
10
Current studies of immunotherapy in head and neck cancer.头颈部癌免疫治疗的当前研究。
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
本文引用的文献
1
A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor.一项关于帕博利珠单抗用于复发性脑膜瘤和孤立性纤维瘤的II期开放标签单臂试验。
Neurooncol Adv. 2024 Sep 16;6(1):vdae154. doi: 10.1093/noajnl/vdae154. eCollection 2024 Jan-Dec.
2
Immunological Tumor Microenvironment of Solitary Fibrous Tumors-Associating Immune Infiltrate with Variables of Prognostic Significance.孤立性纤维瘤的免疫肿瘤微环境——将免疫浸润与具有预后意义的变量相关联
Cancers (Basel). 2024 Sep 21;16(18):3222. doi: 10.3390/cancers16183222.
3
Immunotherapy for Solitary Fibrous Tumor (Hemangiopericytoma): A Unique Treatment Approach for a Rare Central Nervous System Tumor.免疫治疗孤立性纤维瘤（血管外皮细胞瘤）：一种针对罕见中枢神经系统肿瘤的独特治疗方法。
Neurologist. 2024 Jul 1;29(4):250-253. doi: 10.1097/NRL.0000000000000572.
4
Solitary fibrous tumor: Can the new Huang risk stratification system for orbital tumors improve prognostic accuracy in other tumor locations?孤立性纤维瘤：用于眼眶肿瘤的新黄氏风险分层系统能否提高其他肿瘤部位的预后准确性？
Pathol Res Pract. 2024 Feb;254:155143. doi: 10.1016/j.prp.2024.155143. Epub 2024 Jan 19.
5
Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors.全面分析揭示了孤立性纤维瘤的潜在治疗靶点和综合风险分层模型。
Nat Commun. 2023 Nov 18;14(1):7479. doi: 10.1038/s41467-023-43249-4.
6
Atezolizumab for Advanced Alveolar Soft Part Sarcoma.阿替利珠单抗治疗晚期腺泡状软组织肉瘤。
N Engl J Med. 2023 Sep 7;389(10):911-921. doi: 10.1056/NEJMoa2303383.
7
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.派姆单抗治疗罕见和超罕见肉瘤患者（AcSé Pembrolizumab）：一项非随机、开放标签、2 期篮子试验亚组分析。
Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7.
8
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.靶向 PRAME 的 mTCRCAR T 细胞治疗急性髓系白血病。
Blood Adv. 2023 Apr 11;7(7):1178-1189. doi: 10.1182/bloodadvances.2022008304.
9
Toward Better Understanding and Management of Solitary Fibrous Tumor.为了更好地理解和管理孤立性纤维瘤。
Surg Oncol Clin N Am. 2022 Jul;31(3):459-483. doi: 10.1016/j.soc.2022.03.009.
10
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.伴三级淋巴结构的软组织肉瘤中的帕博利珠单抗：PEMBROSARC 试验队列的 2 期研究
Nat Med. 2022 Jun;28(6):1199-1206. doi: 10.1038/s41591-022-01821-3. Epub 2022 May 26.
Zotero 插件